Winship Cancer Institute

Running trials

• Recruiting

  A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread

  NCT07543055· Phase 1· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

  NCT07492680· Phase 2· Bristol-Myers Squibb· Source

• Recruiting

  A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

  NCT07659782· Phase 2· Verastem, Inc.· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

  NCT07581002· Phase 2/3· AbbVie· Source

• Recruiting

  A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.

  NCT07664735· Phase 1· Outpace Bio, Inc.· Source

• Recruiting

  A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  NCT07357727· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

  NCT07393282· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  Study of INCA036978 in Participants With Myeloproliferative Neoplasms

  NCT07441694· Phase 1· Incyte Corporation· Source

• Recruiting

  A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

  NCT07488676· Phase 1/2· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

  NCT07446322· Phase 2· Oncolytics Biotech· Source

• Recruiting

  A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

  NCT07540572· Phase 1· IDEAYA Biosciences· Source

• Recruiting

  A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  NCT06842498· Phase 2· Kyntra Bio· Source

• Recruiting

  A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

  NCT07284758· Phase 2· C4 Therapeutics, Inc.· Source

• Recruiting

  A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  NCT07318558· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

  NCT07280013· Phase 1· C4 Therapeutics, Inc.· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

  NCT07288177· Phase 2· Genmab· Source

• Recruiting

  Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

  NCT07096778· Phase 2· CellCentric Ltd.· Source

• Recruiting

  A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

  NCT07216703· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

  NCT07321106· Phase 1· Cartography Biosciences· Source

• Recruiting

  A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

  NCT07095452· Phase 2/3· AbbVie· Source

• Recruiting

  A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

  NCT07222761· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia

  NCT07033598· Phase 2· Theradex· Source

• Recruiting

  Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma

  NCT07265947· Phase 2· Tyra Biosciences, Inc· Source

• Recruiting

  A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT07225946· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT07252232· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

  NCT07195591· Phase 3· GT Medical Technologies, Inc.· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

  NCT07166094· Phase 3· Genmab· Source

• Recruiting

  A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

  NCT07217171· Phase 1· EvolveImmune United, Inc· Source

• Active, not recruiting

  A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

  NCT07076121· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

  NCT06745908· Phase 3· ImmunityBio, Inc.· Source

• Recruiting

  A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

  NCT07140016· Phase 1· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  A Study of LY4257496 in Participants With Cancer (OMNIRAY)

  NCT07114601· Phase 1· Eli Lilly and Company· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· Phase 3· Pfizer· Source

• Recruiting

  A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

  NCT07094204· Phase 1· Astellas Pharma Inc· Source

• Recruiting

  Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

  NCT06765109· Phase 3· Nuvalent Inc.· Source

• Active, not recruiting

  An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

  NCT06991556· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

  NCT06892522· Phase 1/2· AbbVie· Source

• Recruiting

  Trial of Trastuzumab Deruxtecan in Previously Treated HER2

  NCT06750484· Phase 2· Yale University· Source

• Recruiting

  Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

  NCT06784752· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

  NCT06925737· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia

  NCT06517641· Phase 2· Medical College of Wisconsin· Source

• Recruiting

  Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

  NCT06952660· Phase 4· Pfizer· Source

• Recruiting

  Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  NCT06881784· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

  NCT06926920· Phase 1/2· Gilead Sciences· Source

• Recruiting

  A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

  NCT06827236· Phase 1/2· BioNTech SE· Source

• Recruiting

  A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

  NCT06846671· Phase 3· BeOne Medicines· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

  NCT06824467· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

  NCT06657144· Phase 1· Coherus Oncology, Inc.· Source

• Recruiting

  Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  NCT06890598· Phase 3· Eli Lilly and Company· Source

Showing 50 of 236.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer24 recruiting
• Multiple myeloma22 recruiting
• Ovarian cancer18 recruiting
• Colorectal cancer13 recruiting
• Metastatic breast cancer13 recruiting
• Childhood cancers12 recruiting
• Triple-negative breast cancer11 recruiting
• Prostate cancer10 recruiting
• Acute myeloid leukaemia9 recruiting
• Endometrial cancer8 recruiting
• Melanoma8 recruiting
• Chronic lymphocytic leukaemia6 recruiting
• Gastric and oesophageal cancer6 recruiting
• Bladder cancer5 recruiting
• Pancreatic cancer5 recruiting
• Acute lymphoblastic leukaemia4 recruiting
• Cervical cancer4 recruiting
• Chronic myeloid leukaemia4 recruiting
• Diffuse large B-cell lymphoma4 recruiting
• Myelodysplastic syndromes4 recruiting
• Myeloproliferative neoplasms4 recruiting
• Sarcoma4 recruiting
• Head and neck cancer3 recruiting
• Liver and biliary tract cancer3 recruiting
• Mantle cell lymphoma3 recruiting
• Follicular lymphoma2 recruiting
• Glioblastoma2 recruiting
• Kidney cancer2 recruiting
• Amyloidosis1 recruiting
• Aplastic anaemia1 recruiting
• Brain metastases1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Hearing loss1 recruiting
• Hepatitis C1 recruiting
• HIV1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Meningioma1 recruiting
• Mesothelioma1 recruiting
• Neuroendocrine tumours1 recruiting
• Rheumatoid arthritis1 recruiting
• Sickle cell disease1 recruiting
• Sjögren's disease1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Testicular cancer1 recruiting

Closed trials

• Recruiting

  Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07214779· Phase 3· Incyte Corporation· Source

• Recruiting

  Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

  NCT06282575· Phase 3· Jazz Pharmaceuticals· Source

• Terminated

  A Study of ASP1012 in Adults With Solid Tumors

  NCT06171178· Phase 1· Astellas Pharma Global Development, Inc.· Source

• Terminated

  Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

  NCT05984199· Phase 1/2· Vor Biopharma· Source

• Completed

  A Phase 1 Study of BMF-500 in Adults With Acute Leukemia

  NCT05918692· Phase 1· Biomea Fusion Inc.· Source

• Completed

  PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation

  NCT05639751· Phase 1· Prelude Therapeutics Incorporated· Source

• Completed

  A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors

  NCT05538572· Phase 1· Prelude Therapeutics Incorporated· Source

• Completed

  Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

  NCT05585034· Phase 1· Xencor, Inc.· Source

• Completed

  Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors

  NCT05479812· Phase 1· Werewolf Therapeutics, Inc.· Source

• Recruiting

  A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

  NCT05487170· Phase 1/2· Ranok Therapeutics (Hangzhou) Co., Ltd.· Source

• Completed

  A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

  NCT04919512· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

  NCT05360680· Phase 1· Cue Biopharma· Source

• Completed

  NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

  NCT05340621· Phase 1/2· OnKure, Inc.· Source

• Completed

  A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

  NCT05293496· Phase 1· MacroGenics· Source

• Completed

  Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT05218499· Phase 2/3· Boehringer Ingelheim· Source

• Terminated

  A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

  NCT05181540· Phase 3· Angiocrine Bioscience· Source

• Terminated

  A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

  NCT05169684· Phase 2· Bristol-Myers Squibb· Source

• Terminated

  Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

  NCT04849910· Phase 1/2· Vor Biopharma· Source

• Terminated

  Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer

  NCT04958785· Phase 2· Gilead Sciences· Source

• Completed

  A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

  NCT05091346· Phase 1/2· Eisai Inc.· Source

• Terminated

  KZR-261 in Subjects With Advanced Solid Malignancies

  NCT05047536· Phase 1· Kezar Life Sciences, Inc.· Source

• Terminated

  Open-Label Surufatinib in European Patients With NET

  NCT04579679· Phase 2· Hutchmed· Source

• Recruiting

  A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT04910568· Phase 1· Genentech, Inc.· Source

• Terminated

  Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

  NCT04778397· Phase 3· Gilead Sciences· Source

• Completed

  A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer

  NCT04702737· Phase 1· Amgen· Source

• Completed

  An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.

  NCT04660812· Phase 1/2· Arcus Biosciences, Inc.· Source

• Terminated

  A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

  NCT04776018· Phase 1/2· Takeda· Source

• Terminated

  A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH

  NCT04764474· Phase 1· Hutchmed· Source

• Completed

  INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

  NCT04455841· Phase 1/2· Incyte Corporation· Source

• Terminated

  CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma

  NCT04698187· Phase 2· Regeneron Pharmaceuticals· Source

• Terminated

  Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

  NCT04579757· Phase 1/2· Hutchmed· Source

• Completed

  MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

  NCT04649359· Phase 2· Pfizer· Source

• Completed

  A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

  NCT03776071· Phase 3· Denovo Biopharma LLC· Source

• Completed

  A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

  NCT04539938· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

• Terminated

  Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant

  NCT04511130· Phase 2· Marker Therapeutics, Inc.· Source

• Completed

  A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers

  NCT04466891· Phase 2· Jazz Pharmaceuticals· Source

• Completed

  IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

  NCT04372433· Phase 1· Immune-Onc Therapeutics· Source

• Completed

  REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

  NCT04526106· Phase 1/2· Elevar Therapeutics· Source

• Terminated

  Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma

  NCT04495894· Phase 2· Emory University· Source

• Completed

  A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer

  NCT04322539· Phase 3· Hutchison Medipharma Limited· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

  NCT04300556· Phase 1/2· Eisai Inc.· Source

• Terminated

  Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer

  NCT04421222· Phase 1· ESSA Pharmaceuticals· Source

• Completed

  A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

  NCT04172675· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

  NCT04192344· Phase 1· Abbisko Therapeutics Co, Ltd· Source

• Terminated

  A Study of WVT078 in Patients With Multiple Myeloma (MM)

  NCT04123418· Phase 1· Novartis Pharmaceuticals· Source

• Completed

  Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)

  NCT04003636· Phase 3· Merck Sharp & Dohme LLC· Source

• Terminated

  A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer

  NCT03901469· Phase 2· Zenith Epigenetics· Source

• Completed

  An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

  NCT03915951· Phase 2· Pfizer· Source

• Recruiting

  Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

  NCT03721068· Phase 1· UNC Lineberger Comprehensive Cancer Center· Source

• Completed

  Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer

  NCT03754933· Phase 1/2· GeoVax, Inc.· Source

Showing 50 of 96.

Conditions

Diseases this institution publishes on or runs trials for.

• Multiple myeloma61 works · 46 trials
• Prostate cancer59 works · 30 trials
• Head and neck cancer38 works · 25 trials
• Triple-negative breast cancer36 works · 19 trials
• Metastatic breast cancer34 works · 26 trials
• Kidney cancer32 works · 21 trials
• Neuroendocrine tumours22 works · 7 trials
• Acute myeloid leukaemia21 works · 26 trials
• Myelodysplastic syndromes10 works · 14 trials
• Myeloproliferative neoplasms9 works · 9 trials
• Chronic myeloid leukaemia8 works · 12 trials
• Mantle cell lymphoma6 works · 6 trials
• Follicular lymphoma6 works · 7 trials
• Thymoma and thymic carcinoma4 works · 1 trial